CRISPR gene therapy: applications, limitations, and implications for the future

F Uddin, CM Rudin, T Sen - Frontiers in oncology, 2020 - frontiersin.org
A series of recent discoveries harnessing the adaptive immune system of prokaryotes to
perform targeted genome editing is having a transformative influence across the biological …

[HTML][HTML] Advances in CRISPR therapeutics

M Chavez, X Chen, PB Finn, LS Qi - Nature Reviews Nephrology, 2023 - nature.com
The clustered regularly interspaced short palindromic repeats (CRISPR) renaissance was
catalysed by the discovery that RNA-guided prokaryotic CRISPR-associated (Cas) proteins …

Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer

H Zhang, C Qin, C An, X Zheng, S Wen, W Chen, X Liu… - Molecular cancer, 2021 - Springer
Abstract The 2020 Nobel Prize in Chemistry was awarded to Emmanuelle Charpentier and
Jennifer Doudna for the development of the Clustered regularly interspaced short …

Controversies around epithelial–mesenchymal plasticity in cancer metastasis

ED Williams, D Gao, A Redfern… - Nature Reviews Cancer, 2019 - nature.com
Experimental evidence accumulated over decades has implicated epithelial–mesenchymal
plasticity (EMP), which collectively encompasses epithelial–mesenchymal transition and the …

Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models

YX Lin, Y Wang, J Ding, A Jiang, J Wang… - Science translational …, 2021 - science.org
Increasing clinical evidence has demonstrated that the deletion or mutation of tumor
suppressor genes such as the gene-encoding phosphatase and tensin homolog deleted on …

New and emerging targeted therapies for advanced breast cancer

KH Lau, AM Tan, Y Shi - International journal of molecular sciences, 2022 - mdpi.com
In the United States, breast cancer is among the most frequently diagnosed cancers in
women. Breast cancer is classified into four major subtypes: human epidermal growth factor …

PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges

MA Khan, VK Jain, M Rizwanullah, J Ahmad, K Jain - Drug discovery today, 2019 - Elsevier
Highlights•TNBC represents the most aggressive phenotype of breast cancer.•Conventional
therapy prescribed for breast cancer is not effective in treatment of TNBC.•Specific …

CRISPR/Cas9 system in breast cancer therapy: advancement, limitations and future scope

V Karn, S Sandhya, W Hsu, D Parashar… - Cancer Cell …, 2022 - Springer
Cancer is one of the major causes of mortality worldwide, therefore it is considered a major
health concern. Breast cancer is the most frequent type of cancer which affects women on a …

Dead Cas systems: types, principles, and applications

S Brezgin, A Kostyusheva, D Kostyushev… - International journal of …, 2019 - mdpi.com
The gene editing tool CRISPR-Cas has become the foundation for developing numerous
molecular systems used in research and, increasingly, in medical practice. In particular, Cas …

Novel approaches to epigenetic therapies: from drug combinations to epigenetic editing

A Majchrzak-Celińska, A Warych, M Szoszkiewicz - Genes, 2021 - mdpi.com
Cancer development involves both genetic and epigenetic alterations. Aberrant epigenetic
modifications are reversible, allowing excellent opportunities for therapeutic intervention …